Ascendis Pharma A/S vs Bank of Nova Scotia — how do they compare? Ascendis Pharma A/S trades at $254.5 (market cap $16.67B), while Bank of Nova Scotia trades at $89.03 (market cap $108.32B). The key difference: Bank of Nova Scotia is far larger — about 6.5× Ascendis Pharma A/S's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BNS | |
|---|---|---|
Market Cap | $16.67B | $108.32B |
Sector | Health | Financials |
52-Week High | $277.18 | $90.29 |
52-Week Low | $189.74 | $56.41 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 3.64% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →